I2-imidazoline binding site (I2BS)

The I2-imidazoline binding site (I2BS) is a non-adrenergic pharmacological target located on the outer mitochondrial membrane, where it is physically and functionally associated with monoamine oxidase (MAO), specifically the MAO-B isoform (Raddatz et al., 1995; Parini et al., 1996). Unlike I1-imidazoline receptors, which primarily regulate blood pressure, I2BS is widely distributed in the central nervous system and is particularly abundant in astrocytes and other glial cells (Bousquet et al., 2020). It serves as a key regulator of neuroinflammation and monoamine metabolism, influencing the levels of neurotransmitters like serotonin and dopamine. In clinical contexts, I2BS density is notably upregulated in neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease, often correlating with the progression of glial activation (Tyacke et al., 2022). This makes the site both a therapeutic target for neuroprotection and a diagnostic target for neuroimaging using specific PET tracers like [11C]BU99008. Pharmacological ligands, including CR4056 and 2-BFI, are being investigated for their ability to provide analgesia in chronic pain models and to mitigate cognitive decline (Lanza et al., 2014). Because I2BS is distinct from the catalytic site of MAO, its ligands can modulate cellular signaling without necessarily inhibiting the enzyme's primary oxidative function.

Other names

I2-imidazoline receptorI2RImidazoline receptor type 2I2-site

Allosteric modulation of monoamine oxidase B and regulation of glial cell signaling pathways to suppress neuroinflammation and modulate neurotransmitter levels.